CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia: a Prospective, Single-arm, Single-center, Phase 2 Clinical Trial

CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons. Thus, we supposed that CD19/CD22 bispecific CAR-T cell therapy would be more effective and less relapses would occur in B-ALL or NHL. In this prospective phase 2 clinical trial, we aim to explore the efficacy and safety of CD19/CD22 bispecific CAR-T cell therapy in relapsed/refractory B-ALL or Large B cell lymphoma.

开始日期2022-01-18

申办/合作机构

北京同仁医院管理有限公司

100 项与 CD19/CD22-bispecific CAR-T cells(Beijing Tongren Hospital) 相关的临床结果

登录后查看更多信息

100 项与 CD19/CD22-bispecific CAR-T cells(Beijing Tongren Hospital) 相关的转化医学

登录后查看更多信息

100 项与 CD19/CD22-bispecific CAR-T cells(Beijing Tongren Hospital) 相关的专利（医药）

登录后查看更多信息

项与 CD19/CD22-bispecific CAR-T cells(Beijing Tongren Hospital) 相关的文献（医药）

2023-10-01·Cancer research and treatment

Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient.

作者: Zou, Rui ; Jin, Zhengming ; Xia, Fan ; Wang, Peng ; Kang, Liqing ; Yu, Lei ; Liu, Hailing ; Wu, Depei ; Zhou, Xiao ; Qu, Changju

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive non-Hodgkin's lymphoma that affects the brain, eyes, cerebrospinal fluid, or spinal cord without systemic involvement. The outcome of patients with PCNSL is worse compared to patients with systemic diffuse large B-cell lymphoma. Given potential mortality associated with severe immune effector cell-associated neurotoxicity syndrome (ICANS), patients with PCNSL have been excluded from most clinical trials involving chimeric antigen receptor T-cell (CAR-T) therapy initially. Here, we report for the first time to apply decitabine-primed tandem CD19/CD22 dual-targeted CAR-T therapy with programmed cell death-1 (PD-1) and Bruton's tyrosine kinase (BTK) inhibitors maintenance in one patient with multiline-resistant refractory PCNSL and the patient has maintained complete remission (CR) for a 35-month follow-up period. This case represents the first successful treatment of multiline resistant refractory PCNSL with long-term CR and without inducing ICANS under tandem CD19/CD22 bispecific CAR-T therapy followed by maintenance therapy with PD-1 and BTK inhibitors. This study shows tremendous potential in the treatment of PCNSL and offers a look toward ongoing clinical studies.

2023-04-13·Blood cancer journal

Correction: CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.

作者: Wan, Liping ; Cai, Yu ; Zhu, Lin ; Lu, Yuan ; Zhou, Kun ; Yang, Jun ; Song, Xianmin ; Dong, Baoxia ; Sun, Xuedong ; Niu, Jiahua ; Wang, Haopeng ; Huang, Chongmei ; Ding, Xueying ; Tong, Yin ; Xiang, Fang ; Qiu, Huiying

2023-03-24·Blood cancer journal

CD19/CD22 bispecific CAR-T cells for MRD-positive adult B cell acute lymphoblastic leukemia: a phase I clinical study.

Letter

100 项与 CD19/CD22-bispecific CAR-T cells(Beijing Tongren Hospital) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
弥漫性大B细胞淋巴瘤	临床2期	中国	北京同仁医院管理有限公司	2022-01-18
前体B细胞急性淋巴细胞白血病	临床2期	中国	北京同仁医院管理有限公司	2022-01-18